You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.
10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.
According to the DOJ, the company also accepted a 25-year ban on participating in any federal healthcare program.
23andMe had sued Ancestry.com for, among other things, infringing a patent related to a method for determining the degree to which two people in a database are related.
In a court filing, lawyers say Elizabeth Holmes, the former CEO of Theranos, hasn't paid them in a year, the Mercury News reports.
Personal Genomics alleged that PacBio tried to sublicense the patent-in-suit in the years prior to its launch of the Sequel sequencing platform.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
Retraction Watch reports on the latest goings-on with Carlo Croce's lawsuit against Ohio State University.
The lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.